Rapid Assessment of Drug Susceptibilities of \u3ci\u3eMycobacterium tuberculosis\u3c/i\u3e by Means of Luciferase Reporter Phages by Jacobs, William R., Jr. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Papers in Veterinary and Biomedical Science Veterinary and Biomedical Sciences, Department of 
May 1993 
Rapid Assessment of Drug Susceptibilities of Mycobacterium 
tuberculosis by Means of Luciferase Reporter Phages 
William R. Jacobs Jr. 
Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 
Raul G. Barletta 
University of Nebraska - Lincoln, rbarletta1@unl.edu 
Rupa Udani 
Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 
John Chan 
Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 
Gary Kalkut 
Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers 
 Part of the Veterinary Medicine Commons 
Jacobs, William R. Jr.; Barletta, Raul G.; Udani, Rupa; Chan, John; Kalkut, Gary ; Sosne, Gabriel; Kieser, 
Tobias; Sarkis, Gary J.; Hatfull, Graham F.; and Bloom, Barry R., "Rapid Assessment of Drug Susceptibilities 
of Mycobacterium tuberculosis by Means of Luciferase Reporter Phages" (1993). Papers in Veterinary 
and Biomedical Science. 72. 
https://digitalcommons.unl.edu/vetscipapers/72 
This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and 
Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
William R. Jacobs Jr., Raul G. Barletta, Rupa Udani, John Chan, Gary Kalkut, Gabriel Sosne, Tobias Kieser, 
Gary J. Sarkis, Graham F. Hatfull, and Barry R. Bloom 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
vetscipapers/72 
Tuberculosis remains the largest cause of death in the world from 
a single infectious disease (1) and ac-
counts for as much as 40% of deaths in 
human immunodefi ciency virus (HIV)-
coinfected individuals in some develop-
ing countries (2). Infection with conven-
tional M. tuberculosis can effectively be 
cured with a combination of antitubercu-
losis drugs. Ominously, multidrug-resis-
tant tuberculosis (MDR-TB) strains have 
emerged in several countries, with case 
fatalities ranging from 40 to 60% in im-
munocompetent individuals and >80% 
in immunocompromised individuals (3). 
However, because M. tuberculosis has a 
doubling time of 20 to 24 hours, current 
methodology does not allow determi-
nation of drug susceptibility for 2 to 18 
weeks (4, 5), leaving patients, contacts, 
and health care workers at risk. 
Firefl y luciferase represents one 
of the most effi cient available biolog-
ical reporter molecules because it cata-
lyzes the reaction of luciferin with ade-
nosine triphosphate (ATP) to generate 
photons with a quantum yield of 0.85 
photons per molecule of substrate react-
ed (6). Because of the availability of a 
variety of sensitive light-detection sys-
tems, luciferase has become the standard 
assay for measuring ATP (7). Since the 
molecular cloning of its cDNA (8), the 
fi refl y luciferase gene has been used di-
rectly as a molecular reporter in cells of 
a variety of animal, plant, and bacterial 
species (9). We reasoned that the expres-
sion of luciferase activity could serve as 
a sensitive in vivo measure of ATP in 
mycobacteria and thus allow us to rap-
idly test cellular viability of M. tubercu-
losis after its exposure to different anti-
mycobacterial agents. The optimal use 
the gene could be realized if the lucifer-
Rapid Assessment of Drug Susceptibilities 
of Mycobacterium tuberculosis by Means 
of Luciferase Reporter Phages
William R. Jacobs, Jr.*, Raul G. Barletta†, Rupa Udani, John 
Chan, Gary Kalkut, Gabriel Sosne, Tobias Kieser, Gary J. 
Sarkis, Graham F. Hatfull, Barry R. Bloom
W. R. Jacobs, Jr., R. G. Barletta, R. Udani, J. Chan, G. Kalkut, G. Sosne, B. R. 
Bloom, Howard Hughes Medical Institute, Albert Einstein College of Medicine, 
Bronx, NY 10461. 
T. Kieser, John lnnes lnstitute and AFRC lnstitute of Plant Science Research, 
Norwich NR4 7UH, United Kingdom. 
G. J. Sarkis and G. F. Hatfull, Department of Biological Sciences, University of 
Pittsburgh, Pittsburgh, PA  15230. 
* Corresponding author. 
† Present address: Center for Biotechnology, Department of Veterinary and Biomedical 
Sciences, University of Nebraska–Lincoln, Lincoln, NE 68583
Effective chemotherapy of tuberculosis requires rapid assessment of drug sensitivity because 
of the emergence of multidrug-resistant Mycobacterium tuberculosis. Drug susceptibility 
was assessed by a simple method based on the effi cient production of photons by viable 
mycobacteria infected with specifi c reporter phages expressing the fi refl y luciferase gene. 
Light production was dependent on phage infection, expression of the luciferase gene, and 
the level of cellular adenosine triphosphate. Signals could be detected within minutes after 
infection of virulent M. tuberculosis with reporter phages. Culture of conventional strains 
with antituberculosis drugs, including isoniazid or rifampicin, resulted in extinction of light 
production. In contrast, light signals after luciferase reporter phage infection of drug-resistant 
strains continued to be produced. Luciferase reporter phages may help to reduce the time 
required for establishing antibiotic sensitivity of M. tuberculosis strains from weeks to days 
and to accelerate screening for new antituberculosis drugs.
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ase activity could be measured directly, 
without the need for lysing of the myco-
bacterial cells. To ascertain whether the 
substrate, luciferin, could be transported 
across the intact mycobacterial cell wall, 
we cloned the fi refl y luciferase (FFlux) 
gene downstream of the heat shock pro-
tein 60 (hsp60) promoter in a mycobac-
terial extrachromosomal plasmid vector 
(10) and downstream of the gene 71 pro-
moter of mycobacteriophage L5 (11) in 
a mycobacterial integrating vector (12) 
(Fig. 1A). Both luciferase constructs 
were electroporated into Mycobacterium 
smegmatis (which multiplies ten times 
faster than M. tuberculosis), and lucifer-
ase activity was measured in cells grown 
to logarithmic phase. On addition of
Figure 1. (A) Expression of fi refl y luciferase in 
mycobacteria. Schematic of the extrachromosom-
al plasmid pYUB180 and the integration plasmid 
pGS16. Abbreviations are as follows: Phsp60, pro-
moter of the BCG hsp60 gene; P71, promoters of 
the mycobacteriophage L5’s gene 71; FFlux, fi re-
fl y luciferase gene; aph, aminoglycoside phos-
photransferase that confers kanamycin resistance; 
oriE, ColE1 origin of replication; oriM, mycobacte-
rial plasmid pAL5000 origin of replication; attP and 
int, L5 integration genes; and bla, β-lactamase that 
confers ampicillin resistance to E. coli. (B) Sensi-
tivity of M. smegmatis cells expressing luciferase. 
Plasmids pYUB180 and pGSI6 were electroporat-
ed into the M. smegmatis strain mc2155 (17). Ka-
namycin-resistant transformants were grown to a 
density of approximately 5 x 108 cells per milliliter, 
and tenfold serial dilutions were prepared. Sam-
ples (100 μl) were mixed with 250 μI of 0.1 M so-
dium citrate (pH 5) in a 13 by 75 mm polystyrene 
tube. This mixture was placed in the luminometer 
(Monolight 2010; Analytical Luminescence Labo-
ratory, San Diego, California), 100 μI of 1 mM lu-
ciferin (Sigma, St. Louis, Missouri) was injected 
into the tube, and the luciferase activity was mea-
sured. Mycobacterium smegmatis cultures are in-
dicated as follows: mc2155 (pYUB180), black; 
mc2155 (pGS16), diagonal; and mc2155 cells 
alone, white. 
Figure 2. Infection of mycobacteria with LRPs 
results in the production of light. (A) Schemat-
ic of the luciferase reporter mycobacteriophages 
phAE39 and phAE40. Luciferase reporter phag-
es were made by construction of shuttle phasmids 
in which an E. coli cosmid pYUB216 (18) was in-
serted into a nonessential region of the mycobac-
teriophage TM4. The cosmid pYUB216 contains 
(i) FFlux in a transcriptional fusion with the hsp60 
promoter of BCG, (ii) a ColE1 origin and an ampi-
cillin resistance gene (Ap) for replication and se-
lection in E. coli, (iii) a bacteriophage λ cos se-
quence, and (iv) a unique Bcl I site. The phAE39 
shuttle phasmid was constructed in a manner sim-
ilar to that described previously (14), with Bcl I-
digested pYUB216 ligated to TM4 DNA that had 
been partially digested by SAU 3Al. The result-
ing shuttle phasmid, phAE39, like its parent TM4, 
readily forms plaques of M. tuberculosis, but does 
not effi ciently form plaques on BCG. Spontane-
ous host range mutants of phAE39 could be iso-
lated at frequencies of 10–6 to 10–7, and one such 
mutant was isolated and designated phAE40. 
(B) Light production in mycobacteria after infection with the luciferase reporter phage phAE40. High ti-
ters of phAE40 were prepared as described previously for TM4 phages (19). Mycobacterium smegma-
tis, mc2155 cells, and BCG-Pasteur cells were grown in roller bottles to approximately 5 × 107 cells per 
milliliter in Middlebrook 7H9 broth with ADC enrichment and 0.05% Tween-80 [M-ADC-TW broth (19)] at 
37°C. Either the M. smegmatis or the BCG cells were harvested by centrifugation and washed twice in 
M-ADC broth (containing no Tween-80). The resulting pellet was resuspended in the original volume of 
M-ADC broth. The cells were diluted fi vefold into fresh M-ADC broth and were allowed to incubate over-
night standing at 37°C. (Tween-80 seems to remove the receptors, and we have found that optimal activ-
ities are attained if the cells have a chance to grow in the absence of Tween-80. This procedure possibly 
allows regeneration of phage receptors.) One milliliter of washed cells (approximately 5 × 107 cells) was 
mixed with 0.1 ml of phAE40 particles [5 × 108 plaque-forming units (PFU) per milliliter] that had been 
concentrated on CsCl gradients to attain a multiplicity of infection of 10. The cell-phage mixture was in-
cubated at 37°C. Beginning at the time of the addition of the phAE40, we removed 0.1-ml samples at the 
times designated in the graph. Luciferase activity was measured as described in Figure 1 and plotted. 
Filled circles, BCG cells alone; open circles, BCG cells plus phAE40; fi lled triangles, mc2155 cells alone; 
fi lled squares, mc2155 cells plus phAE40; open squares, phAE40 alone. 
Figure 3. Comparison of the kinetics of light production of 
drug-sensitive BCG cells to that of drug-resistant BCG mu-
tant cells after phage infection. Spontaneous mutants of 
BCG-Pasteur strains were isolated on Middlebrook 7H10 
agar containing either rifampicin (50 μg/ml), streptomycin 
(250 μg/ml), or isoniazid (5 μg/ml). The rifampicin-, strep-
tomycin-, or isoniazid-resistant mutants were purifi ed and 
designated as mc2768, mc2767, and mc2765, respectively. 
All three mutants and the BCG parent were grown to mid-
logarithmic phase, harvested, and washed as described 
in Figure 2 BCG cells (circles) and mutant cells (squares) 
were incubated in the presence (open symbols) or ab-
sence (fi lled symbols) of rifampicin, streptomycin, or iso-
niazid. (A) The mc2768 cells and the BCG cells were in-
cubated standing at 37°C in the presence or absence of 
rifampicin (50 μg/ml) for 24 hours. A 0.5-ml sample (ap-
proximately 5 × 107 viable cells) was mixed with 0.1 ml 
(5 × 108 PFU) of phAE40 particles, and luciferase activity 
was determined as described in Figure 2 and plotted as a 
representative experiment. This experiment was repeated 
a minimum of three times. The absolute background and 
peak luminescence signals varied approximately twofold 
between experiments, but the ratios of signals of drug-re-
sistant relative to susceptible cells were constant (20- to 
100-fold depending on the strain). (B) The mc2767 cells 
and the BCG cells were incubated standing at 37°C in the 
presence or absence of streptomycin (250 μg/ml) for 24 
hours. (C) The mc2765 cells and the BCG cells were incu-
bated standing at 37°C in the presence or absence of iso-
niazid (50 μg/ml) for 24 hours.
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luciferin, luciferase activity was read-
ily measured from intact mycobacte-
rial cells infected with both the extra-
chromosomal and the integrating vectors 
(Fig. 1B). Serial dilutions indicated that 
it was possible to detect as few as 500 to 
5000 M. smegmatis cells expressing fi re-
fl y luciferase (Fig. 1B), establishing that 
the luciferase-luciferin system could be 
developed as a sensitive reporter system 
for ATP in mycobacteria. 
The ability to make use of the lucifer-
ase reporter gene to assess drug suscep-
tibilities in clinical isolates requires an 
effi cient means for delivering the lucif-
erase gene into the M. tuberculosis cells. 
Phages offer an ideal vehicle with which 
to deliver a foreign gene to every cell in 
a bacterial culture (13). We have previ-
ously developed shuttle phasmid vectors 
from a variety of mycobacteriophages 
that can be genetically manipulated in 
Escherichia coli and then used to deliver 
the recombinant DNA into mycobacteria 
by infection with high effi ciency (14). 
A shuttle phasmid, phAE39, was con-
structed from mycobacteriophage TM4, 
which forms plaques on both the fast-
growing mycobacterium M. smegmatis
and the slow-growing mycobacterium 
M. tuberculosis, by insertion of an E. 
coli cosmid into which the FFlux gene 
had been inserted downstream of the 
strong hsp60 promoter (Fig. 2A). A host 
range mutant of phAE39, phAE40, was 
isolated that was capable of infecting ba-
cillus Calmette-Guerin (BCG) vaccine 
strains, in addition to M. smegmatis and 
M. tuberculosis (Fig. 2A). To test wheth-
er these resulting luciferase reporter 
phages (LRPs) could elicit the produc-
tion of light after infection of mycobac-
teria, we mixed the LRPs with M. smeg-
matis cells and then exposed the mixture 
at different times to luciferin. Light sig-
nals could be detected by means of a 
luminometer within minutes of infec-
tion and increased 1000-fold within 2 
hours (Fig. 2B). The signals are two to 
three orders of magnitude lower than an 
equivalent number of cells harboring the 
luciferase plasmids, probably as a result 
of less effi cient gene expression or of in-
hibitory effects of the phage on host cell 
metabolism or ATP levels. The similarity 
of the kinetics of light production in M. 
smegmatis and BCG (Fig. 2B) suggests 
that differences in gene expression may 
not be the principal determinant in the 
tenfold slower growth of BCG (or M. tu-
berculosis) relative to M. smegmatis. 
It then became feasible to test wheth-
er the luciferase reporter phages were 
capable of distinguishing drug-resistant 
from drug-susceptible organisms. Mu-
tants of BCG were selected that were re-
sistant to rifampicin, streptomycin, or 
isoniazid (Fig. 3). When wild-type BCG 
and the mutants were cultured for 24 
hours with the antibiotics, the parental 
strain did not produce any signal, where-
as light was produced by the drug-resis-
tant mutants (Fig. 3). Finally, the lucif-
erase reporter phage assay was tested on 
clinically derived M. tuberculosis strains, 
both singly and multiply drug-resistant 
(MDR). The results (Fig. 4) established 
that luciferase reporter phages can rap-
idly reveal the patterns of drug suscep-
tibility or resistance of M. tuberculosis 
strains. The apparent lower activity of 
M. tuberculosis relative to BCG (Fig. 3) 
primarily refl ects the use of a luminome-
ter with different light unit defi nition and 
sensitivity rather than an intrinsic differ-
ence between bacterial strains (15). 
Because of the emergence of multi-
drug-resistant strains, it has become in-
creasingly important to rapidly ascertain 
patterns of drug susceptibility. These ob-
servations demonstrate the use of lucifer-
ase reporter mycobacteriophages as sim-
ple tools for the rapid determination of 
drug susceptibility profi les of M. tuber-
culosis. It is expected that this method-
ology will be adapted for use on clinical 
isolates with a minimum time of culture. 
This might be achieved by an increase 
in the sensitivity of the assay or by en-
gineering of better characterized myco-
bacteriophages, such as L5 [whose com-
plete DNA sequence is known (16)], to 
permit higher expression of luciferase. 
The technology could be adapted for use 
in developing countries either through 
use of inexpensive luminometers or of 
sensitive fi lm technology (7). In addi-
tion, luciferase phages or M. tuberculo-
sis strains expressing luciferase genes 
may permit rapid screening of drugs for 
antituberculosis activity. 
REFERENCES AND NOTES
1. C J. L. Murray, K. Styblo, A. Rouillon, in 
Disease Control Priorities in Develop-
ing Countries, D. T. Jamison and W. H. 
Mosley, Eds. (Oxford Univ. Press for 
the World Bank, New York, in press); C. 
J. L. Murray, K. Styblo, A. Rouillon, Bull. 
Figure 4. Use of luciferase reporter phage assay 
to  distinguish drug-sensitive from drug-resistant M. 
tuberculosis strains. The following M. tuberculosis 
strains were grown in a biological safety level 3 con-
tainment facility: (i) The virulent drug-sensitive M. tu-
berculosis Erdman strain; (ii) strain 92-2025, a singly 
isoniazid-resistant strain; and  (iii) an MDR strain of 
tuberculosis that has been shown to be resistant to 
rifampicin, streptomycin, isoniazid, ethambutol, and 
ethionamide and the cause of several nosocomial 
outbreaks in New York City (20). The Erdman strain 
was subcultured from the starter culture by inocula-
tion of 0.4 ml into 20 ml of Middlebrook 7H9 broth 
containing OADC enrichment (Difco Laboratories, 
Detroit, Michigan) plus 0.5 Tween-80 (M-OADC-
TW broth). The 92-2025 and the MDR strains, which 
grow more slowly than the Erdman strain, were sub-
cultured by inoculation of 2 ml into 20 ml M-OADC-
TW broth. All three cultures were grown standing 
at 37°C for 7 to 8 days. The cells were washed as 
described above and 0.5. resuspended in 0.5× the 
original volume. Washed cells (0.2 ml) were inocu-
lated into 0.7 ml of M-OADC broth (19) and incubat-
ed in 13 by 100 mm polypropylene tubes in a heat-
ing block in a biohazard hood for 48 hours. Rifampicin, streptomycin, or isoniazid were added to fi nal 
concentrations of 2 μg/ml, 6 μg/ml, and 1 μg/ml, respectively. After 48 hours of incubation, 0.1 ml of 
phAE40 particles (1 × 1011 particles) were added to attain a multiplicity of infection of 1000. Samples of 
100 μI were removed at 1, 3, and 5 hours after addition of the phage and were mixed with 250 μI of 0.1 
M sodium citrate (pH 5) in a Lumacuvette (Lumac BV, Netherlands). One hundred microliters of 1 mM lu-
ciferin were added, and the Lumacuvette was plugged with cotton. The tube was placed in a Lumac Bio-
counter (M1500 P), and readings were recorded as described above. (The Lumac biocounter has dimen-
sions that permit it to fi t in a standard biohazard hood.) The light production followed kinetics similar to 
the BCG experiments, and the readings at 3 and 5 hours differed by no more than twofold. The results at 
3 hours are shown for the Erdman (A), 92-2025 (B), and the MDR (C) M. tuberculosis strains. A repeat-
ed experiment gave similar results, with the samples cultured in the absence of drug exhibiting an 80-fold 
greater luminescence than the cells cultured with rifampicin or streptomycin and greater than tenfold lu-
minescence relative to those cultured with isoniazid at 3 and 5 hours. Open bars, cells alone; fi lled bars, 
cells plus LRPs; diagonal lines, cells plus rifampicin plus LRPs; cross-hatching, cells plus streptomycin 
plus LRPs; squares, cells plus isoniazid plus LPRs. 
822 JACOBS ET AL. IN SCIENCE 260 (MAY 7, 1993)
Int. Union Tuberc. 65, 6 (1990).
2. Y. Abouya et al., Am. Rev Respir. Dis. 
145, 617 (1992). 
3. T. R. Frieden et al., N. Engl. J. Med. 328, 
521 (1993); M. Goble et al., ibid., p. 
527; M. D. lseman and L. A. Madsen, 
Clin. Chest. Med. 10, 341 (1992); M. D. 
lseman and J. A. Sbarbaro, Curr. Clin. 
Top. Infect. Dis. 12, 188 (1992). 
4. L. Heifets, Drug Susceptibility in the Che-
motherapy of Mycobacterial Infections, 
L. Heifets, Ed. (CRC Press, Ann Arbor, 
MI, 1991), pp. 89–122. 
5. Morbid. Mortal Weekly Rep. 41, 507 
(1992). 
6. J. W. Hastings, T. O. Baldwin, M. Z. Nico-
li, Methods Enzymol. 57, 135 (1978). 
7. M. A. DeLuca and W. D. McElroy, eds., 
Bioluminescence and Chemilumines-
cence (Academic Press, New York, 
1981), P E Stanley et al., J. Biolumin. 
Chemilumin. 3, 131 (1989), G. G. G. 
Thorpe, T. P. Whitehead, R. Penn, L. J. 
Dricka, Clin. Chem. 30, 806 (1984). 
8. J. R. deWet, K. V. Wood, D. R. Helins-
ki, M. DeLuca, Proc. Natl. Acad. Sci. 
U.S.A. 82, 7870 (1985), J. R. deWet, 
K. V. Wood, M. DeLuca, D. R. Helins-
ki, S, Subramani, Mol. Cell. Biol. 7, 725 
(1987). 
9. D. W. Ow et al., Science 234, 856 (1986); 
J. Gould and S. Subramani, Anal. Bio-
chem. 175, 5 (1988); A. J. Palomeres, 
M. A. DeLuca, D. R. Helinski, Gene 
81, 55 (1989); A. G. Dileia et al., Nu-
cleic Acids Res. 16, 4159 (1988), A. R. 
Brasier, J. E. Tate, J. F. Habener, Bio-
Techniques 7, 1116 (1989); K. V. Wood, 
Y. A. Lam, W. D. McElroy, J. Biolumin. 
Chemilumin. 5, 107 (1990); T. Kondo, 
N. Takahashi, M. Muramatsu, Nucleic 
Acids Res. 20, 5729 (1992); A. J. Mill-
er, S. R. Short, N. H. Chua, S. A. Kay, 
Plant Cell 4, 1075 (1992), J. Engebre-
cht, M. Simon, M. Sherman, Science 
227, 1345 (1985); J. J. Shaw and C. 
J. Kado, BioTechniques 4, 560 (1986), 
G. Schmetterer, C. P. Wolk, J. Elhai, J. 
Bacteriol. 167, 411 (1986), O. A Carmi, 
G. S. A. B. Stewart, S. Ulitzur, J. Kuhn, 
J. Bacteriol. 169, 2165 (1987). 
10. C. K. Stover et al., Nature 351, 456 
(1991). 
11. M. K. Donnelly-Wu, W. R. Jacobs, Jr., 
G. F. Hatfull, Mol. Microbiol. 7, 407 (1 
993).
12. M. H. Lee, L. Pascopella, W. R. Jacobs, 
Jr., G. F. Hatfull, Proc. Natl. Acad. Sci. 
U.S.A. 88, 3111 (1991).
13. S. Ulitzer and J. Kuhn, in Biolumines-
cence and Chemiluminescence, New 
Perspectives, J. Sclomerick, R. Andre-
sen, A. Kapp, M. Ernst, W. G. Woods, 
eds. (Wiley, New York, 1987), pp. 463–
472; C. P. Kodikara, H. H. Crew, G. S. 
A. B. Stewart, FEMS Microbiol. Lett. 83, 
261 (1991). 
14. W. R. Jacobs, Jr., M. Tuckman, B. R. 
Bloom, Nature 327, 532 (1987); S. B. 
Snapper et al., Proc Natl. Acad. Sci. 
U.S.A. 85, 6987 (1988). 
15. W. R. Jacobs, Jr., et al., unpublished 
data. 
16. G. F. Hatfull and G. J. Sarkis, Mol. Mi-
crobiol. 7, 395 (1993). 
17. S. B. Snapper, R. E. Melton, S. Musta-
fa, T. Kieser, W. R. Jacobs, Jr., Mol. Mi-
crobiol. 4, 1911 (1990). 
18. R. G. Barletta et al., unpublished data.
19. W. R. Jacobs, Jr., et al., Methods Enzy-
mol. 204, 537 (1991). 
20. Morbid. Mortal. Weekly Rep., in press. 
21. We thank J. McKittrick, D. Alland, L. Or-
nstein, K. Stover, and R. Davis for help-
ful discussions and R. Good, J. Kilburn, 
and D. Alland for providing strains. Sup-
ported by National Institutes of Health 
grants A127235 (to W.R.J. and G.F.H) 
and A128927 (to G.F.H.); National Co-
operative Drug Discovery Group grants 
UOlA130189 (to W.R.J.) and A123545 
(to B.R.B.); and grants from the Special 
Program for Tropical Diseases and Pro-
gram for Vaccine Development of the 
World Health Organization (to W.R.J. 
and B.R.B.). 
Submitted January 22, 1993, 
accepted March 29, 1993.
